Aurobindo Pharma Ltd
NSE:AUROPHARMA

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Watchlist
Price: 1 223.7 INR 0.55% Market Closed
Market Cap: 710.7B INR
Have any thoughts about
Aurobindo Pharma Ltd?
Write Note

Aurobindo Pharma Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aurobindo Pharma Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Short-Term Investments
â‚ą3.1B
CAGR 3-Years
17%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Short-Term Investments
â‚ą76.7B
CAGR 3-Years
53%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Short-Term Investments
â‚ą77.9B
CAGR 3-Years
40%
CAGR 5-Years
36%
CAGR 10-Years
18%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Short-Term Investments
â‚ą117.4B
CAGR 3-Years
44%
CAGR 5-Years
21%
CAGR 10-Years
22%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Short-Term Investments
â‚ą3.3B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
6%
M
Mankind Pharma Ltd
NSE:MANKIND
Short-Term Investments
â‚ą30B
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aurobindo Pharma Ltd
Glance View

Market Cap
717B INR
Industry
Pharmaceuticals

Aurobindo Pharma Ltd., a prominent player in the global generic pharmaceutical market, began its journey in 1986 with a vision to make high-quality medicines accessible to patients around the world. Over the years, the company has transformed into a diversified pharmaceutical powerhouse, producing a wide range of generic formulations, active pharmaceutical ingredients (APIs), and complex generics. Headquartered in Hyderabad, India, Aurobindo leverages robust research and development capabilities, along with an extensive manufacturing footprint that spans several countries, allowing it to cater to diverse markets, including the United States and Europe. With a commitment to quality and regulatory compliance, Aurobindo's products cover multiple therapeutic areas, including anti-retrovirals, antibiotics, cardiovascular, and central nervous system disorders, making it a well-regarded name in the industry. For investors, Aurobindo Pharma represents an attractive opportunity, given its consistent revenue growth and strategic focus on innovation. The company's investment in technology and its ability to navigate stringent regulatory landscapes enable it to maintain a competitive edge in the generics sector. Furthermore, Aurobindo's expanding portfolio of complex generics positions it to capture higher margins in the marketplace, while its strong presence in emerging markets ensures ongoing demand for its offerings. As the global healthcare landscape continues to evolve, Aurobindo Pharma's adaptability and commitment to sustainable growth make it a compelling choice for those looking to invest in a resilient and forward-thinking pharmaceutical enterprise.

AUROPHARMA Intrinsic Value
1 081.41 INR
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Aurobindo Pharma Ltd's Short-Term Investments?
Short-Term Investments
3.1B INR

Based on the financial report for Jun 30, 2024, Aurobindo Pharma Ltd's Short-Term Investments amounts to 3.1B INR.

What is Aurobindo Pharma Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
-25%

Over the last year, the Short-Term Investments growth was -29%. The average annual Short-Term Investments growth rates for Aurobindo Pharma Ltd have been 17% over the past three years , -25% over the past five years .

Back to Top